These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 2562651)

  • 1. A phase I/II study of recombinant tumor necrosis factor and recombinant interferon gamma in patients with AIDS-related complex.
    Kaplan LD; Abrams DI; Sherwin SA; Kahn J; Volberding PA
    Biotechnol Ther; 1989-1990; 1(3):229-36. PubMed ID: 2562651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.
    Weiner LM; Li W; Holmes M; Catalano RB; Dovnarsky M; Padavic K; Alpaugh RK
    Cancer Res; 1994 Aug; 54(15):4084-90. PubMed ID: 8033141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer.
    Abbruzzese JL; Levin B; Ajani JA; Faintuch JS; Saks S; Patt YZ; Edwards C; Ende K; Gutterman JU
    Cancer Res; 1989 Jul; 49(14):4057-61. PubMed ID: 2500234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human TNF-alpha: preclinical studies and results from early clinical trials.
    Saks S; Rosenblum M
    Immunol Ser; 1992; 56():567-87. PubMed ID: 1550875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: results of a trial terminated by excessive toxicity.
    Abbruzzese JL; Levin B; Ajani JA; Faintuch JS; Pazdur R; Saks S; Edwards C; Gutterman JU
    J Biol Response Mod; 1990 Oct; 9(5):522-7. PubMed ID: 2123922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy.
    Hallahan DE; Vokes EE; Rubin SJ; O'Brien S; Samuels B; Vijaykumar S; Kufe DW; Phillips R; Weichselbaum RR
    Cancer J Sci Am; 1995; 1(3):204-9. PubMed ID: 9166477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical RTNF therapy of superficial bladder cancer. A phase I study of recombinant tumor necrosis factor administered intravesically to patients with superficial bladder cancer.
    Grampsas SA; Kahn K; Crawford ED
    Online J Curr Clin Trials; 1994 Mar; Doc No 117():[4845 words; 36 paragraphs]. PubMed ID: 8136939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.
    Rinehart J; Margolin KA; Triozzi P; Hersh E; Campion M; Resta D; Levitt D
    Clin Cancer Res; 1995 Oct; 1(10):1139-44. PubMed ID: 9815905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of i.v. administered recombinant gamma interferon in cancer patients.
    Kurzrock R; Quesada JR; Rosenblum MG; Sherwin SA; Gutterman JU
    Cancer Treat Rep; 1986 Dec; 70(12):1357-64. PubMed ID: 3098417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
    Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
    Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local treatment of liver metastases with recombinant tumour necrosis factor (rTNF): a phase one study.
    IJzermans JN; van der Schelling GP; Scheringa M; Splinter TA; Marquet RL; Jeekel J
    Neth J Surg; 1991 Aug; 43(4):121-5. PubMed ID: 1944989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon.
    Small EJ; Weiss GR; Malik UK; Walther PJ; Johnson D; Wilding G; Kuzel T; Bajamonde A; Paton V
    Cancer J Sci Am; 1998; 4(3):162-7. PubMed ID: 9612597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
    Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
    Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of recombinant human gamma interferon (IFN-gamma 4A) in patients with advanced malignancy.
    Perez R; Lipton A; Harvey HA; Simmonds MA; Romano PJ; Imboden SL; Giudice G; Downing MR; Alton NK
    J Biol Response Mod; 1988 Jun; 7(3):309-17. PubMed ID: 3134513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor.
    Schiller JH; Storer B; Tutsch K; Arzoomanian R; Alberti D; Feierabend C; Spriggs D
    Semin Oncol; 1994 Oct; 21(5 Suppl 8):9-14. PubMed ID: 7524159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.
    Safdar A; Rodriguez GH; Lichtiger B; Dickey BF; Kontoyiannis DP; Freireich EJ; Shpall EJ; Raad II; Kantarjian HM; Champlin RE
    Cancer; 2006 Jun; 106(12):2664-71. PubMed ID: 16691620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion.
    Gérain J; Liénard D; Pampallona S; Baumgartner M; Rüegg C; Buurman WA; Eggermont A; Lejeune F
    Cytokine; 1997 Dec; 9(12):1034-42. PubMed ID: 9417816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.